QC
APGE icon

Quadrature Capital’s Apogee Therapeutics APGE Stock Holding History

Quadrature Capital’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,829
Closed -$513K – 1030
2025
Q2 		$513K Buy
+11,829
New +$450K 0.01% 568

Other funds holding APGE

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Quadrature Capital's APGE Position: Q3 2025 in Review

Quadrature Capital sold out of Apogee Therapeutics (APGE) in Q3 2025, closing a stake of 11,829 shares — an estimated $513K sold.

Quadrature Capital first reported a position in APGE in Q2 2025 and held it in 1 quarter. The position peaked at $513K in Q2 2025. 174 funds tracked by Wall St. Rank hold APGE as of Q3 2025.

  • Quadrature Capital reported no remaining Apogee Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Quadrature Capital sold 11,829 Apogee Therapeutics shares in Q3 2025, an estimated $513K.
  • Quadrature Capital first reported a position in Apogee Therapeutics in Q2 2025 and held it in 1 quarter.
  • Quadrature Capital's Apogee Therapeutics position peaked at $513K in Q2 2025.
  • 174 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2025.

Based on Quadrature Capital's 13F filing for Q3 2025, filed 13 Nov 2025.